Seattle's Immune Design teams up with Merck, stock soars
Seattle biotech company Immune Design (Nasdaq: IMDZ) announced a new partnership Monday that will help further the company's immunotherapy treatments.
Immune Design has entered into a clinical collaboration with New Jersey-based pharmaceutical company Merck (NYSE: MRK) to evaluate the safety and efficacy of two of the Seattle company's immunotherapy products in Phase 1 clinical trails for patients with non-Hodgkin's lymphoma and melanoma.
The trials will examine how each of those two products —…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Annie Zak Source Type: news
More News: American Health | Biotechnology | Health | Health Management | Immunotherapy | Lymphoma | Melanoma | Merck | Non-Hodgkin's Lymphoma | Partnerships | Skin Cancer